scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Phytochemicals As Chemosensitizers: From Molecular Mechanism to Clinical Significance

25 Feb 2013-Antioxidants & Redox Signaling (Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA)-Vol. 18, Iss: 11, pp 1307-1348
TL;DR: An overview of the clinical relevance of chemosensitization is provided, giving special reference to the phenolic phytochemicals, curcumin, genistein, epigallocatechin gallate, quercetin, emodin, and resveratrol, which are potential candidates due to their ability to regulate multiple survival pathways without inducing toxicity.
Abstract: This review provides an overview of the clinical relevance of chemosensitization, giving special reference to the phenolic phytochemicals, curcumin, genistein, epigallocatechin gallate, quercetin, emodin, and resveratrol, which are potential candidates due to their ability to regulate multiple survival pathways without inducing toxicity. We also give a brief summary of all the clinical trials related to the important phytochemicals that emerge as chemosensitizers. The mode of action of these phytochemicals in regulating the key players of the death receptor pathway and multidrug resistance proteins is also abridged. Rigorous efforts in identifying novel chemosensitizers and unraveling their molecular mechanism have resulted in some of the promising candidates such as curcumin, genistein, and polyphenon E, which have gone into clinical trials. Even though considerable research has been conducted in identifying the salient molecular players either contributing to drug efflux or inhibiting DNA repair and apoptosis, both of which ultimately lead to the development of chemoresistance, the interdependence of the molecular pathways leading to chemoresistance is still the impeding factor in the success of chemotherapy. Even though clinical trials are going on to evaluate the chemosensitizing efficacy of phytochemicals such as curcumin, genistein, and polyphenon E, recent results indicate that more intense study is required to confirm their clinical efficacy. Current reports also warrant intense investigation about the use of more phytochemicals such as quercetin, emodin, and resveratrol as chemosensitizers, as all of them have been shown to modulate one or more of the key regulators of chemoresistance.
Citations
More filters
Journal ArticleDOI
TL;DR: The challenges for the clinical detection of MDR will be to find new biomarkers and to determine new evaluation systems before the drug resistance emerges, which will likely combine the existing therapies with drugs originated from MDR mechanisms.

537 citations


Cites background from "Phytochemicals As Chemosensitizers:..."

  • ...Autophagy is an evolutionarily conserved mechanism for degradation for the maintenance of intracellular homeostasis [9]....

    [...]

  • ...Chemotherapeutic drugs induce autophagy along with apoptosis, and autophagy exerts its cyto-protective effect by degrading the drug molecules, helping cancer cells evade apoptosis [9]....

    [...]

Journal ArticleDOI
TL;DR: The aberrant flow conditions caused by sIA geometry are the likely cause of the endothelial dysfunction, which results in accumulation of cytotoxic and pro-inflammatory substances into the sIA wall, as well as thrombus formation.
Abstract: Saccular intracranial aneurysms (sIA) are pouch-like pathological dilatations of intracranial arteries that develop when the cerebral artery wall becomes too weak to resist hemodynamic pressure and distends Some sIAs remain stable over time, but in others mural cells die, the matrix degenerates, and eventually the wall ruptures, causing life-threatening hemorrhage The wall of unruptured sIAs is characterized by myointimal hyperplasia and organizing thrombus, whereas that of ruptured sIAs is characterized by a decellularized, degenerated matrix and a poorly organized luminal thrombus Cell-mediated and humoral inflammatory reaction is seen in both, but inflammation is clearly associated with degenerated and ruptured walls Inflammation, however, seems to be a reaction to the ongoing degenerative processes, rather than the cause Current data suggest that the loss of mural cells and wall degeneration are related to impaired endothelial function and high oxidative stress, caused in part by luminal thrombosis The aberrant flow conditions caused by sIA geometry are the likely cause of the endothelial dysfunction, which results in accumulation of cytotoxic and pro-inflammatory substances into the sIA wall, as well as thrombus formation This may start the processes that eventually can lead to the decellularized and degenerated sIA wall that is prone to rupture

356 citations


Cites background from "Phytochemicals As Chemosensitizers:..."

  • ...This occurs also as an initial response to many of the degenerative changes occurring during aging, although in most of these situations the actual disease is related to subsequent loss of medial smooth muscle cells [71]....

    [...]

  • ...Collagen fibers exposed to mechanical stress eventually degenerate [71], and therefore need to be repaired and maintained by continuous synthesis of new collagen....

    [...]

Journal ArticleDOI
TL;DR: RES serves as a novel solution to reverse the DOX-resistance of gastric cancer via preventing EMT by modulating PTEN/Akt signaling pathway.
Abstract: Gastric cancer is one of the major causes of cancer-related mortality worldwide. Most of patients presenting with inoperable gastric cancers rely on systemic chemotherapy for prolongation of survival. Doxorubicin (DOX) is one of the important agents against gastric cancer. Acquired DOX-resistance severely impedes the chemotherapeutic effect, invariably leading to poor prognosis. Resveratrol (RES) as a kind of phytoalexin has demonstrated anti-tumor functions in breast cancer and myeloid leukemia, but its function and mechanism are still unknown in gastric cancer treatment. CCK8 assay was used to detect the cytotoxicity of DOX and RES to gastric cancer cells. DOX-resistant subclone cell line (SGC7901/DOX) was derived from SGC7901 cells exposed to stepwise increasing concentrations of DOX treatment. We measured the migratory capabilities of SGC7901/DOX cells by Cell scratch test and Transwell assay. SGC7901/DOX cells were treated with DOX, RES, neither or both. Then we analyzed cell survival by CCK8 assay, colony formation by Colony-forming assay, cell apoptosis by Annexin-V-FITC and PI dual staining assay and cell migration by Cell scratch test and Transwell assay. Western blotting was conducted to detect the protein expressions of PTEN/Akt signaling pathway and EMT-related markers. Immunofluorescence was performed to confirm the EMT-related markers expressions. The xenograft model was used to assess the effect of DOX and RES in vivo. The key molecules associated with proliferation, apoptosis and EMT were evaluated by immunohistochemistry in tumor specimens. SGC7901/DOX cells acquired drug resistance and enhancive migratory capability. RES enabled SGC7901/DOX cells to regain DOX sensitivity, mitigated the aggressive biological features, promoted cell apoptosis in vitro and inhibited tumor growth in vivo. Mechanistic studies revealed that SGC7901/DOX cells underwent epithelial-mesenchymal transition (EMT) which was induced by Akt activation, and through activating PTEN, RES inhibited the Akt pathway, and then achieved the reversion of EMT. RES serves as a novel solution to reverse the DOX-resistance of gastric cancer via preventing EMT by modulating PTEN/Akt signaling pathway. DOX-RES combined treatment provides a promising future for gastric cancer patients to postpone drug resistance and prolong survival.

175 citations


Cites background from "Phytochemicals As Chemosensitizers:..."

  • ...A number of phytochemicals available exhibit chemopreventive effect and sensitize cancer cells toward DOX [13]....

    [...]

Journal ArticleDOI
TL;DR: The results revealed the synergistic effect of DOX/Cur-NPs on the apoptosis, proliferation and angiogenesis of HCC, indicating that Cur might reverse multidrug resistance (MDR) through these pathways.

139 citations

Journal ArticleDOI
TL;DR: A novel lipid nanoparticles loaded with doxorubicin (DOX) and curcumin (Cur) (a chemosensitizer) simultaneously are developed and the efficacy of chemotherapy in liver cancer is examined, suggesting the simultaneous delivery of DOX and Cur by DOX/Cur-NPs might be a promising treatment for liver cancer.
Abstract: Liver cancer is a leading cause of cancer deaths worldwide. The combination therapy of cytotoxic and chemosensitizing agents loaded in nanoparticles has been highlighted as an effective treatment for different cancers. However, such studies in liver cancer remain very limited. In our study, we aim to develop a novel lipid nanoparticles loaded with doxorubicin (DOX) (an effective drug for liver cancer) and curcumin (Cur) (a chemosensitizer) simultaneously, and we examined the efficacy of chemotherapy in liver cancer. DOX and Cur codelivery lipid nanoparticles (DOX/Cur-NPs) were successfully prepared using a high-pressure microfluidics technique, showing a mean particle size of around 90 nm, a polydispersity index 90% for both DOX and Cur. The blank lipid nanoparticles were nontoxic, as determined by a cell cytotoxicity study in human normal liver cells L02 and liver cancer cells HepG2. In vitro DOX release studies revealed a sustained-release pattern until 48 hours in DOX/Cur-NPs. We found enhanced cytotoxicity and decreased inhibitory concentration (IC)50 in HepG2 cells and reduced cytotoxicity in L02 cells treated with DOX/Cur-NPs, suggesting the synergistic effects of DOX/Cur-NPs compared with free DOX and DOX nanoparticles (NPs). The optimal weight ratio of DOX and Cur was 1:1. Annexin-V-fluorescein isothiocyanate/propidium iodide double staining showed enhanced apoptosis in HepG2 cells treated with DOX/Cur-NPs compared with free DOX and DOX-NPs. An in vivo experiment showed the synergistic effect of DOX/Cur-NPs compared with DOX-NPs on liver tumor growth inhibition. Taken together, the simultaneous delivery of DOX and Cur by DOX/Cur-NPs might be a promising treatment for liver cancer.

124 citations


Cites background from "Phytochemicals As Chemosensitizers:..."

  • ...However, the clinical application of DOX has been severely hindered because of its critical cardiotoxicity, narrow therapeutic window, and the development of MDR.13 In some cancer cell studies, improved MDR and increased apoptosis have been reported with treatment of the NP-based combination therapy of DOX and chemosensitizers (ie, TNF-related apoptosis-inducing ligand, verapamil, Bcl-2 small interfering [si]RNA, and P-gp siRNA).14–17 Curcumin (Cur), the polyphenol constituent of the perennial herb Curcuma longa, exhibits antioxidant, antiinflammatory, antiangiogenic, antimicrobial, and anticancer activities.18 It also acts as a chemosensitizer to suppress the overexpression of P-glycoprotein to reverse MDR in ovarian adenocarcinoma cells.19 However, its extremely low water solubility and poor bioavailability have impeded its clinical use.20 To date, several studies have demonstrated the enhanced anticancer efficacy of the codelivery of DOX and Cur in nanocarriers, including polymeric NPs21–23 and liposomes24 in chronic myelogenous leukemia, lung, and breast cancers....

    [...]

  • ...of cytotoxic and chemosensitizing agents exhibited better performance in the intracellular microenvironment, and are thus highlighted as more effective for tumor localization and for overcoming MDR.(6,7) Despite the benefits of combination therapy, the nanoparticle (NP)-based targeted drug delivery (nanocarriers) has been designed to increase drug accumulation at tumor sites to improve permeability and retention,(8) pharmacokinetic profiles, and reduce side effects....

    [...]

  • ...For example, the combination of anticancer agents targeting multiple pathways, or a combination of chemotherapy with chemosensitizers has been shown to modulate different signaling pathways in cancer cells, which is beneficial to overcome multidrug resistance (MDR), maximize the therapeutic effect, and reduce side effects.4–6 Compared with a multiagent combination, the combination correspondence: Wei liu college of life science and Technology, huazhong University of science and Technology, 1037 luoyu road, Wuhan 430074, People’s republic of china Tel +86 27 877 921 47 Fax +86 27 877 922 34 email wliu@hust.edu.cn Yusang li Department of Pharmacology, college of Pharmacy, south-central University for Nationalities, 182 Minyuan road, Wuhan 430074, People’s republic of china Tel +86 27 6784 2332 Fax +86 27 6784 2332 email liys2006@mail.scuec.edu.cn In te rn at io na l J ou rn al o f N an om ed ic in e do w nl oa de d fr om h ttp s: //w w w .d ov ep re 2 F or p er so na l u se o nl y. International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com Dovepress Dovepress 258 Zhao et al of cytotoxic and chemosensitizing agents exhibited better performance in the intracellular microenvironment, and are thus highlighted as more effective for tumor localization and for overcoming MDR.6,7 Despite the benefits of combination therapy, the nanoparticle (NP)-based targeted drug delivery (nanocarriers) has been designed to increase drug accumulation at tumor sites to improve permeability and retention,8 pharmacokinetic profiles, and reduce side effects.9,10 Therefore, the delivery of a chemotherapeutic agent and chemosensitizer using nanocarriers has been suggested as a novel and promising strategy in cancer treatment.11,12 DOX, an anthracycline antibiotic, is one of the most efficacious drugs in the treatment of liver cancer....

    [...]

References
More filters
Journal ArticleDOI
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Abstract: Background The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Methods We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2. We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab. Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women). Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women). Results The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression (median, 7.4 ...

10,532 citations


"Phytochemicals As Chemosensitizers:..." refers background in this paper

  • ...Moreover, elevated p21Waf1 levels conferred by HER2/neu signaling can also bring about changes in the G2/M transition, and help evade cell death induced by chemotherapeutic drugs (99)....

    [...]

  • ...Emodin-mediated reduction in tyrosine phosphorylation of HER2/neu suppresses the proliferation of HER2/neu-overexpressing nonsmall cell lung cancer cells and sensitizes these cells to the cytotoxic activity of cisplatin in a synergistic manner (329)....

    [...]

  • ...Tamoxifen Hormone (SERM) Uterine and endometrial cancer, liver damage, agranulocytosis, and hemolytic anemia (46) NF-jB (172), Akt (50), HER2/neu (62, 276)...

    [...]

  • ...Emodin is a tyrosine kinase inhibitor and is shown to inhibit HER2/neu tyrosine kinase activity that leads to a preferential suppression of growth, represses the transformation of HER2/neu overexpressing breast cancer cells (328), and sensitizes these cells to paclitaxel in nude mice models (330)....

    [...]

  • ...Signaling through human epidermal growth factor receptor 2/neuregulin (HER2/neu) is another growth factor 1312 VINOD ET AL. receptor-mediated signal transduction pathway that has been implicated in conferring resistance to conventional chemotherapy....

    [...]

Journal ArticleDOI
TL;DR: Enhanced bioavailability of curcumin in the near future is likely to bring this promising natural product to the forefront of therapeutic agents for treatment of human disease.
Abstract: Curcumin, a polyphenolic compound derived from dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Phase I clinical trials have shown that curcumin is safe even at high doses (12 g/day) in humans but exhibit poor bioavailability. Major reasons contributing to the low plasma and tissue levels of curcumin appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination. To improve the bioavailability of curcumin, numerous approaches have been undertaken. These approaches involve, first, the use of adjuvant like piperine that interferes with glucuronidation; second, the use of liposomal curcumin; third, curcumin nanoparticles; fourth, the use of curcumin phospholipid complex; and fifth, the use of structural analogues of curcumin (e.g., EF-24). The latter has been reported to have a rapid absorption with a peak plasma half-life. Despite the lower bioavailability, therapeutic efficacy of...

4,275 citations


"Phytochemicals As Chemosensitizers:..." refers background in this paper

  • ...Curcumin Vinblastine Cervical, breast Yes In vitro (7) In vivo (0) No In vitro (0) In vivo (0) 5-flurocytosine Colon cancer Yes In vitro (2) In vivo (0) No In vitro (0) In vivo (0) Mitomycin C Lung, breast, cervical Yes In vitro (5) In vivo (3) No In vitro (0) In vivo (0) Bortezomib Multiple myeloma Yes In vitro (5) In vivo (1) No In vitro (0) In vivo (0) Thalidomide Multiple myeloma Yes In vitro (1) In vivo (1) No In vitro (0) In vivo (0) Gemcitabine Pancreatic, bladder, prostate Yes In vitro (3) In vivo (2) No In vitro (0) In vivo (0) BCG Bladder Yes In vitro (1) In vivo (1) No In vitro (0) In vivo (0) Paclitaxel Bladder, ovarian, prostate, cervical, breast Yes In vitro (7) In vivo (5) No In vitro (1) In vivo (0) Docetaxel Lung, breast, ovarian Yes In vitro (2) In vivo (5) No In vitro (1) In vivo (0) TRAIL Bladder, prostate, renal, ovarian Yes In vitro (8) In vivo (1) No In vitro (0) In vivo (0) Etoposide Gastric, Glioma, cervical, breast Yes In vitro (5) In vivo (1) No In vitro (0) In vivo (0) Cisplatin Lung, HNSCC, ovarian, breast, fibrosarcoma, glioma, esophageal, neuroblastoma, hepatic Yes In vitro (12) In vivo (0) No In vitro (0) In vivo (0) Doxorubicin Gastric, breast, leukemia, glioma, lung, neuroblastoma, hepatic, leukemia, osteosarcoma, uterine sarcoma, laryngeal Yes In vitro (19) In vivo (1) No In vitro (2) In vivo (0) 5-FU Prostate, colon, esophageal, pancreatic, gastric Yes In vitro (12) In vivo (2) No In vitro (0) In vivo (0) Oxaliplatin Colon cancer Yes In vitro (6) In vivo (0) No In vitro (0) In vivo (0) Dasatinib Colorectal cancer Yes In vitro (2)...

    [...]

  • ...Cisplatin Gallbladder cancer, lung cancer, prostate cancer, Merkel cell carcinoma Yes In vitro (5) In vivo (1) No In vitro (1) In vivo (0) Carboplatin Gallbladder cancer, ovarian cancer Yes In vitro (1) In vivo (0) No In vitro (1) In vivo (0) Oxaliplatin Gallbladder cancer Yes In vitro (1) In vivo (0) No In vitro (0) In vivo (0) 5-FU Melanoma, lung cancer, Merkel cell carcinoma Yes In vitro (3) In vivo (0) No In vitro (0) In vivo (0) Mitomycin C Lung cancer Yes In vitro (1) In vivo (0) No In vitro (0) In vivo (0) Gefitinib Lung cancer Yes In vitro (1) In vivo (0) No In vitro (0) In vivo (0) TRAIL Hepatic cancer, cervical cancer Yes In vitro (1) In vivo (0) No In vitro (0) In vivo (0) Arsenic trioxide Leukemia, cervical cancer, gastric carcinoma, oesophageal carcinoma Yes In vitro (6) In vivo (1) No In vitro (0) In vivo (0) Paclitaxel Ovarian cancer, breast cancer, melanoma Yes In vitro (2) In vivo (1) No In vitro (1) In vivo (0) Doxorubicin Merkel cell carcinoma, lung cancer Yes In vitro (2) In vivo (0) No In vitro (1) In vivo (0) Etoposide Lung cancer Yes In vitro (1) In vivo (0) No In vitro (0) In vivo (0) Celecoxib Cholangiocarcinoma Yes In vitro (1) In vivo (0) No In vitro (0) In vivo (0)...

    [...]

  • ...Resveratrol TRAIL Colon, neuroblastoma, medulloblastoma, glioblastoma, melanoma, breast, prostate, pancreatic, leukemia Yes In vitro (10) In vivo (1) No In vitro (0) In vivo (0) 5-FU Cholangiocarcinoma, liver cancer, colon, neuroblastoma Yes In vitro (6) In vivo (2) No In vitro (1) In vivo (0) Paclitaxel Lung, nasopharyngeal, epidermoid, leukemia, non-Hodgkin’s lymphoma, multiple myeloma Yes In vitro (6) In vivo (0) No In vitro (6) In vivo (1) Doxorubicin Leukemia, ovarian, uterine, breast, cervical, liver Yes In vitro (7) In vivo (0)...

    [...]

  • ...Quercetin Doxorubicin Breast, neuroblastoma, leukemia, melanoma, colon Yes In vitro (8) In vivo (3) No In vitro (3) In vivo (0) TRAIL Lung, prostate, hepatocellular carcinoma, colon, leukemia, glioma, non-Hodgkin’s lymphoma, Yes In vitro (10) In vivo (0) No In vitro (1) In vivo (0) Temozolomide/DTIC Astrocytoma, melanoma Yes In vitro (4) In vivo (0) No In vitro (6) In vivo (1) Paclitaxel Hepatoma, colon, breast Yes In vitro (1) In vivo (1) No In vitro (2) In vivo (0) Cisplatin Colon, HNSCC, ovarian, leukemia, Ewing’s tumor Yes In vitro (6) In vivo (0) No In vitro (0) In vivo (0) Bortezomib Leukemia, multiple myeloma, melanoma Yes In vitro (0) In vivo (0) No In vitro (3) In vivo (0) Etoposide Colon carcinoma, Ewing’s tumor Yes In vitro (3) In vivo (3) No In vitro (0) In vivo (0) Vincristine Breast cancer Yes In vitro (1) In vivo (1) No In vitro (0) In vivo (0)...

    [...]

  • ...Curcumin formulations in liposomes, micelles, and phospholipid complexes as well as a combination of curcumin with low doses of piperine (the black pepper alkaloid) have also provided promising results (6)....

    [...]

Journal ArticleDOI
TL;DR: In this article, the authors identify a 2.4-kb mRNA that encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that they termed breast cancer resistance protein (BCRP).
Abstract: MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent reduction in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein. RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells. The mRNA encodes a 663-aa member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP). Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells. BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.

2,235 citations

Journal ArticleDOI
TL;DR: The regulation of ROS levels by NF-κB targets and various ways in which ROS have been proposed to impact NF-σκB signaling pathways are reviewed.
Abstract: NF-κB proteins are a family of transcription factors that are of central importance in inflammation and immunity. NF-κB also plays important roles in other processes, including development, cell growth and survival, and proliferation, and is involved in many pathological conditions. Reactive Oxygen Species (ROS) are created by a variety of cellular processes as part of cellular signaling events. While certain NF-κB-regulated genes play a major role in regulating the amount of ROS in the cell, ROS have various inhibitory or stimulatory roles in NF-κB signaling. Here we review the regulation of ROS levels by NF-κB targets and various ways in which ROS have been proposed to impact NF-κB signaling pathways.

2,219 citations


"Phytochemicals As Chemosensitizers:..." refers background in this paper

  • ...The NF-jB pathway, activated by different signaling events, is one of the major down-stream effector pathways regulating ROS signaling, leading to chemoresistance (204)....

    [...]

Journal ArticleDOI
TL;DR: What are the molecular mechanisms of tumour resistance to apoptosis and how can the authors use this knowledge to resensitize tumour cells to cancer therapy?
Abstract: Every cell in a multicellular organism has the potential to die by apoptosis, but tumour cells often have faulty apoptotic pathways. These defects not only increase tumour mass, but also render the tumour resistant to therapy. So, what are the molecular mechanisms of tumour resistance to apoptosis and how can we use this knowledge to resensitize tumour cells to cancer therapy?

1,948 citations


"Phytochemicals As Chemosensitizers:..." refers background in this paper

  • ...and a detailed account of the same is reviewed elsewhere (112)....

    [...]